---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-24-000032"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:17:50.665220+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CareDx reports FY2023 revenue $280.3M, exceeding guidance; Q4 net loss includes $96.3M patent accrual

## Summary
- Full-year revenue $280.3M, down 13% YoY; Testing Services revenue $209.7M, down 20%.
- Q4 revenue $65.6M, down 20% YoY; net loss $118.1M, including $96.3M patent infringement accrual.
- Non-GAAP net loss per share Q4 $0.17; full-year adjusted EBITDA loss $38.0M.
- Cash and marketable securities $235.4M; repurchased 2.9M shares for $27.5M in 2023.
- Seeking judicial review of January 2024 jury verdict on patent ‘544; Medicare coverage added for HeartCare and AlloSure Lung.

## SEC filing metadata
- accession: 0001217234-24-000032
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723424000032/0001217234-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723424000032/cdna-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-24-000032
- JSON: https://secwatch.observer/filing/0001217234-24-000032.json
- Plain text: https://secwatch.observer/filing/0001217234-24-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.